Scientific Article
previous document  unige:106704  next document
add to browser collection
Title

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Authors
Dodel, Richard
Rominger, Axel
Bartenstein, Peter
Barkhof, Frederik
Blennow, Kaj
Förster, Stefan
Winter, Yaroslav
Bach, Jan-Philipp
show hidden authors show all authors [1 - 23]
Published in The Lancet Neurology. 2013, vol. 12, no. 3, p. 233-243
Abstract Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.
Keywords AgedAged, 80 and overAlzheimer Disease/diagnosis/drug therapy/immunologyAmyloid beta-Peptides/bloodArea Under CurveDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansImmunoglobulins, Intravenous/administration & dosage/adverse effects/bloodMaleMiddle AgedPlacebosSeverity of Illness Index
Identifiers
PMID: 23375965
Full text
Article (Published version) (746 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Citation
(ISO format)
DODEL, Richard et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. In: The Lancet Neurology, 2013, vol. 12, n° 3, p. 233-243. https://archive-ouverte.unige.ch/unige:106704

42 hits

0 download

Update

Deposited on : 2018-07-27

Export document
Format :
Citation style :